The global chemotherapy market is a critical segment of the oncology therapeutics field, focusing on the use of chemical substances to treat cancer. As of 2023, the market is valued at approximately USD 70 billion, driven by increasing cancer prevalence, advancements in drug formulations, and the development of targeted therapies. The Chemotherapy Market was valued at USD 8.2 billion in 2022. The industry is projected to grow from USD 8.81 billion in 2023 to USD 15.72 billion by 2032, reflecting a compound annual growth rate (CAGR) of 7.50% during the forecast period (2024 - 2032).Key factors propelling this growth include rising healthcare expenditures, increasing awareness and early diagnosis, and ongoing research and development in novel chemotherapeutic agents and combination therapies. The market is highly competitive, with major players like Roche, Pfizer, and Novartis leading innovations in personalized and precision medicine.
Chemotherapy is a treatment which uses drugs in killing cancerous cells in the body. The goal of the treatment can be for curative, palliative, and control purposes. It is also colloquially known as ‘chemo’. The global chemotherapy market report by Market Research Future (MRFR) looks at the various types of cancers and the impact of chemotherapy on their treatment for the period of 2019 to 2024 (forecast period).
Market Outlook
It can exhibit a stupendous growth rate of 7.50% during the forecast period. Huge prevalence of cancer, large allocation of funds for research on cancer, and introduction of new reimbursement and medical insurance schemes are major drivers of the market. Patent expiry of drugs, public awareness of combination therapies, and government campaigns are other key factors expected to facilitate market growth.
Clinical trials are estimated to define the success of the combination of chemotherapy with new drugs. According to a recent publication in the Journal of Clinical Oncology, the addition of pembrolizumab to the mix of platinum methotrexate and chemotherapy for the treatment of patients with advanced squamous non-small-cell lung cancer (NSLC) had led to increased survival rate by a certain degree.
Competition Outlook
Chemotherapy Market Players Eli Lilly and Company, GlaxoSmithKline PLC, Novartis AG, Merck & Co. Inc., Johnson & Johnson Services Inc, Bristol-Myers Squibb Company, Celgene Corporation, Pfizer Inc., Sanofi S.A., and F. Hoffmann-La Roche Ltd are notable players of the global chemotherapy market. The market is a mix of large and small startup aiming to disrupt the market through new drugs and their compatibility with chemo. In addition, investments are at an all-time high in clinical trials with the success of the drugs extending the survival line of patients. The aim to bring down the cost of chemotherapy drugs will also be pivotal in determining the new leader of the market in the coming years.
Segmentation Analysis
The global chemotherapy market is segmented into drug class, route of administration, indication, and end user.
On the basis of drug class, the market is segmented into topoisomerase inhibitors, alkylating agents, mitotic inhibitors, antitumor antibiotic, and antimetabolites. The alkylating agents segment is expected to lead the market and score a substantial CAGR of 11.83% to reach USD 20,360.32 million by the end of 2024.
By indication, the market is segmented into stomach cancer, ovarian cancer, lung cancer, breast cancer, colorectal cancer, prostate cancer, lymphoma, leukemia, and others. Lung cancer accounted for the largest market share and expects to display a CAGR of 11.88% during the forecast period.
On the basis of route of administration, the market is segmented into intraperitoneal, intravenous, intraventricular/intrathecal, subcutaneous, oral, intra-muscular, intravesicular, and topical. Intravenous accounted for the largest market share. However, the oral segment is expected to grow at the fastest CAGR of 11.95% during the forecast period.
On the basis of end user, the market is segmented into hospitals & clinics, specialty centers, and others.
Regional Analysis
Geographically the chemotherapy market covers the potential of the treatment across the Americas, Europe, Asia Pacific (APAC), and the Middle East and Africa (MEA).
The Americas accounted for 41.04% share in 2018. It can notch a CAGR of 10.88% during the assessment period with North America accountable for the growth spurt. The large number of cancer cases, availability of advanced treatment, and attractive medical reimbursement schemes can fuel the Americas chemotherapy market growth.
The Europe chemotherapy market can exceed a valuation of USD 18,292.73 million by 2024. Rise in the number of cancer cases, the increase in healthcare expenditure, and government awareness campaigns can have an indelible impact on the regional market. Germany and France are the biggest revenue getters of the market.
APAC is expected to showcase growth at a rapid clip owing to increased funding in China and India. The aging population and demand for advanced treatment methods can influence the regional market growth. Although the MEA region accounts for the lowest market share, the rise in the elderly population can amp up the chemotherapy treatments in the region.
Browse Related Reports:
Single use bioprocessing Market
Medical devices reimbursement Market
medical vending machines Market
For More Information, Please Visit @ Market Research Future
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian